Docosahexanoic acid-induced coronary arterial dilation: Actions of 17S-hydroxy docosahexanoic acid on K+ channel activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 3, 2011, Pages 891-899

  Li, Xiang ^a   Hong, Song ^b   Li, Pin Lan ^a   Zhang, Yang ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; GLIBENCLAMIDE; HYDROXY DOCOSAHEXAENOIC ACID; IBERIOTOXIN; LIPOXYGENASE; POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CONDUCTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DILATATION; COW; ENDOTHELIUM; ENDOTHELIUM CELL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; TANDEM MASS SPECTROMETRY;

ANIMALS; CATTLE; CORONARY VESSELS; DOCOSAHEXAENOIC ACIDS; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; POTASSIUM CHANNEL BLOCKERS; VASODILATION; VASODILATOR AGENTS;

EID: 79951987663     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.176461     Document Type: Article

References (37)

1. Abeywardena MY and Head RJ (2001) Longchain n-3 polyunsaturated fatty acids and blood vessel function. Cardiovasc Res 52:361-371. (Pubitemid 33153099)
2. Brown AM and Birnbaumer L (1990) Ionic channels and their regulation by G protein subunits. Annu Rev Physiol 52:197-213. (Pubitemid 20103534)
3. Campbell WB, Deeter C, Gauthier KM, Ingraham RH, Falck JR, and Li PL (2002) 14,15-Dihydroxyeicosatrienoic acid relaxes bovine coronary arteries by activation of K(Ca) channels. Am J Physiol Heart Circ Physiol 282:H1656-H1664. (Pubitemid 34654832)
4. Connor WE, DeFrancesco CA, and Connor SL (1993) N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann NY Acad Sci 683:16-34. (Pubitemid 23236650)
5. De Caterina R and Zampolli A (2001) n-3 fatty acids: antiatherosclerotic effects. Lipids 36:S69-S78. (Pubitemid 34106212)
6. Engler MB and Engler MM (2000) Docosahexaenoic acid-induced vasorelaxation in hypertensive rats: mechanisms of action. Biol Res Nurs 2:85-95.
7. Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Hittner SB, Deeter C, Sharma KK, Gauthier KM, and Campbell WB (2003) Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am J Physiol Heart Circ Physiol 284:H337-H349. (Pubitemid 36076302)
8. Fleischhauer FJ, Yan WD, and Fischell TA (1993) Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol 21:982-989. (Pubitemid 23106165)
9. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, and Campbell WB (2002) 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90:1028-1036. (Pubitemid 34633870)
10. 2+ release by M1 muscarinic receptor activation in coronary arterial smooth muscle. J Vasc Res 40:28-36.
11. Gebremedhin D, Ma YH, Falck JR, Roman RJ, VanRollins M, and Harder DR (1992) Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle. Am J Physiol Heart Circ Physiol 263:H519-H525.
12. Geiger J, Zou AP, Campbell WB, and Li PL (2000) Inhibition of cADP-ribose formation produces vasodilation in bovine coronary arteries. Hypertension 35:397-402. (Pubitemid 30054206)
13. Hamill OP, Marty A, Neher E, Sakmann B, and Sigworth FJ (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391:85-100. (Pubitemid 11012976)
14. Harrison N and Abhyankar B (2005) The mechanism of action of omega-3 fatty acids in secondary prevention post-myocardial infarction. Curr Med Res Opin 21:95-100. (Pubitemid 40327510)
15. Hirafuji M, Machida T, Hamaue N, and Minami M (2003) Cardiovascular protective effects of n-3 polyunsaturated fatty acids with special emphasis on docosahexaenoic acid. J Pharmacol Sci 92:308-316. (Pubitemid 37086713)
16. Holub DJ and Holub BJ (2004) Omega-3 fatty acids from fish oils and cardiovascular disease. Mol Cell Biochem 263:217-225. (Pubitemid 39256160)
17. Hong S, Gronert K, Devchand PR, Moussignac RL, and Serhan CN (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 278:14677-14687. (Pubitemid 36799790)
18. Horrocks LA and Yeo YK (1999) Health benefits of docosahexaenoic acid (DHA). Pharmacol Res 40:211-225. (Pubitemid 29435720)
19. Jackson WF (2005) Potassium channels in the peripheral microcirculation. Microcirculation 12:113-127.
20. Jeerakathil TJ and Wolf PA (2001) Prevention of strokes. Curr Atheroscler Rep 3:321-327.
21. Kang JX and Leaf A (2000) Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 71:202S-207S.
22. 2+-activated K+ channels and voltage-dependent K+ channels in rat coronary artery smooth muscle cells. Acta Pharmacol Sin 30:314-320.
23. Leaf A, Xiao YF, Kang JX, and Billman GE (2003) Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids. Pharmacol Ther 98:355-377. (Pubitemid 36638548)
24. Li PL and Campbell WB (1997) Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 80:877-884.
25. McDonald TF, Pelzer S, Trautwein W, and Pelzer DJ (1994) Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev 74:365-507. (Pubitemid 24127646)
26. McLennan P, Howe P, Abeywardena M, Muggli R, Raederstorff D, Mano M, Rayner T, and Head R (1996) The cardiovascular protective role of docosahexaenoic acid. Eur J Pharmacol 300:83-89. (Pubitemid 26130477)
27. Nageswari K, Banerjee R, and Menon VP (1999) Effect of saturated, omega-3 and omega-6 polyunsaturated fatty acids on myocardial infarction. J Nutr Biochem 10:338-344. (Pubitemid 29255983)
28. Nordøy A, Marchioli R, Arnesen H, and Videbaek J (2001) n-3 polyunsaturated fatty acids and cardiovascular diseases. Lipids 36:S127-S129. (Pubitemid 34106222)
29. Rapp JH, Connor WE, Lin DS, and Porter JM (1991) Dietary eicosapentaenoic acid and docosahexaenoic acid from fish oil. Their incorporation into advanced human atherosclerotic plaques. Arteriosclerosis Thrombosis 11:903-911.
30. Salem N Jr, Litman B, Kim HY, and Gawrisch K (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36:945-959. (Pubitemid 33065196)
31. Shimokawa H and Vanhoutte PM (1989) Dietary omega 3 fatty acids and endothelium-dependent relaxations in porcine coronary arteries. Am J Physiol Heart Circ Physiol 256:H968-H973.
32. Simopoulos AP (2002) Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21:495-505.
33. Thid D, Benkoski JJ, Svedhem S, Kasemo B, and Gold J (2007) DHA-induced changes of supported lipid membrane morphology. Langmuir 23:5878-5881. (Pubitemid 46868652)
34. Toro L, Marijic J, Nishimaru K, Tanaka Y, Song M, and Stefani E (2002) Aging, ion channel expression, and vascular function. Vascul Pharmacol 38(1):73-80. (Pubitemid 36398292)
35. Wu KT, Huang CT, Wei J, Tsait LM, Hsu CH, Chen YC, Yangs JM, and Lin CI (2007) Vasodilator action of docosahexaenoic acid (DHA) in human coronary arteries in vitro. Chin J Physiol 50:164-170.
36. Ye D, Zhang D, Oltman C, Dellsperger K, Lee HC, and VanRollins M (2002) Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J Pharmacol Exp Ther 303:768-776. (Pubitemid 35231254)
37. Yokoshiki H, Sunagawa M, Seki T, and Sperelakis N (1998) ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells. Am J Physiol Cell Physiol 274:C25-C37.